

AMENDMENT NO. \_\_\_\_\_ Calendar No. \_\_\_\_\_

Purpose: In the nature of a substitute.

**IN THE SENATE OF THE UNITED STATES—118th Cong., 2d Sess.**

**S. 4436**

To improve the safety of infant formula through testing of infant formula for microorganisms and toxic elements, and for other purposes.

Referred to the Committee on \_\_\_\_\_ and  
ordered to be printed

Ordered to lie on the table and to be printed

AMENDMENT IN THE NATURE OF A SUBSTITUTE intended  
to be proposed by \_\_\_\_\_

Viz:

1 Strike all after the enacting clause and insert the fol-  
2 lowing:

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Protect Infant For-  
5 mula from Contamination Act”.

6 **SEC. 2. NOTIFICATIONS FOR TESTING OF INFANT FOR-**  
7 **MULA.**

8 Section 412(e) of the Federal Food, Drug, and Cos-  
9 metic Act (21 U.S.C. 350a(e)) is amended—

10 (1) in paragraph (1), in the matter following  
11 subparagraph (B)—

1 (A) by striking “promptly”;

2 (B) by inserting “, within 1 business day  
3 of acquiring such knowledge” after “such  
4 knowledge”; and

5 (C) by striking “the infant formula” and  
6 inserting “an infant formula”;

7 (2) by redesignating paragraph (2) as para-  
8 graph (5); and

9 (3) by inserting after paragraph (1) the fol-  
10 lowing:

11 “(2) If the result of any testing of a sample from  
12 any production aggregate of finished infant formula prod-  
13 uct is confirmed as a positive analytical result for any  
14 microorganism for which finished product testing is re-  
15 quired under section 106.55(e) of title 21, Code of Federal  
16 Regulations (or any successor regulation), the manufac-  
17 turer shall—

18 “(A) within 1 business day of acquiring a con-  
19 firmed positive analytical result, notify the Secretary  
20 of such result, regardless of whether such product  
21 has left an establishment subject to the control of  
22 the manufacturer;

23 “(B) promptly consult with the Secretary for  
24 proper isolation of the affected product, and, as the

1 Secretary may require, cease distribution and prop-  
2 erly dispose of the affected product; and

3 “(C) promptly provide to the Secretary results  
4 and isolates from a positive sample of such product  
5 or the whole genetic sequence from any confirmed  
6 positive analytical result.

7 “(3) Not later than 1 business day after receipt by  
8 the Secretary of a notification under paragraph (2)(A),  
9 the Secretary shall respond to the manufacturer of the in-  
10 fant formula to begin discussions regarding investigation  
11 and corrective action, and, as appropriate, share the find-  
12 ings of the Secretary with the manufacturer.

13 “(4) Not later than 90 days after receipt of a notifi-  
14 cation under paragraph (1) or (2), the Secretary shall con-  
15 firm, including through the collection of documentation,  
16 that the manufacturer submitting the notification per-  
17 formed, or is performing, an appropriate investigation and  
18 corrective action, if applicable. The Secretary shall con-  
19 sider, as part of the review of the root cause investigation,  
20 the analytical method used to conduct laboratory testing  
21 and, as appropriate, the potential for cross contamination  
22 of the sample by handling and testing. The manufacturer  
23 shall make such documentation available to the Secretary  
24 electronically and for inspection under section 704.”

1 **SEC. 3. REPORTING TO IMPROVE THE SAFETY AND SUPPLY**  
2 **OF INFANT FORMULA.**

3 Section 412 of the Federal Food, Drug, and Cosmetic  
4 Act (21 U.S.C. 350a) is amended by adding at the end  
5 the following:

6 “(n) REPORTING TO IMPROVE THE SAFETY AND  
7 SUPPLY OF INFANT FORMULA.—

8 “(1) PROGRESS REPORT.—Not later than 180  
9 days after the date of enactment of the Protect In-  
10 fant Formula from Contamination Act, the Sec-  
11 retary shall issue a progress report on implementa-  
12 tion of the recommendations to improve the safety  
13 and supply of infant formula contained in the report  
14 titled, ‘Immediate National Strategy to Increase the  
15 Resiliency of the U.S. Infant Formula Market’,  
16 issued by the Food and Drug Administration in  
17 March 2023. Such progress report shall include ad-  
18 ditional authorities or resources that the Secretary  
19 may require for purposes of improving the safety  
20 and supply of infant formula.

21 “(2) QUARTERLY REPORTS ON SUPPLY  
22 CHAIN.—Not later than 270 days after the date of  
23 enactment of the Protect Infant Formula from Con-  
24 tamination Act, and not less frequently than quar-  
25 terly for the 5-year period thereafter, the Secretary  
26 shall submit a report on the most current, critical

1 supply chain data for infant formula, including in-  
2 stock rates, to—

3 “(A) the Committee on Health, Education,  
4 Labor, and Pensions; the Committee on Agri-  
5 culture, Nutrition, and Forestry; and the Sub-  
6 committee on Agriculture, Rural Development,  
7 Food and Drug Administration, and Related  
8 Agencies of the Committee on Appropriations of  
9 the Senate; and

10 “(B) the Committee on Energy and Com-  
11 merce; the Committee on Agriculture; and the  
12 Subcommittee on Agriculture, Rural Develop-  
13 ment, Food and Drug Administration, and Re-  
14 lated Agencies of the Committee on Appropria-  
15 tions of the House of Representatives.

16 “(3) CONSULTATION.—The Secretary shall en-  
17 gage with the Department of Agriculture and other  
18 relevant agencies of the Federal Government regard-  
19 ing ongoing efforts to address immediate formula  
20 needs and build long-term resiliency into the infant  
21 formula market.

22 “(4) REPORTS ON ADEQUACY OF SUPPLY.—Not  
23 later than 1 year, 3 years, and 5 years after the date  
24 of enactment of the Protect Infant Formula from  
25 Contamination Act, the Secretary shall—

1           “(A) engage with public stakeholders, in-  
2           fant formula manufacturers, and other stake-  
3           holders, as determined by the Secretary, to de-  
4           termine evidence-based practices that can be  
5           implemented to maximize infant formula supply  
6           and infant safety, which may include the value  
7           of high frequency testing for purposes of identi-  
8           fying contamination events and bracketing po-  
9           tentially contaminated product, the impact of  
10          corrective action on contamination events, and  
11          evidence-based recommendations for enhancing  
12          infant formula supply and safety; and

13           “(B) submit a report to the committees de-  
14          scribed in subparagraphs (A) and (B) of para-  
15          graph (2) that identifies the modifications to  
16          manufacturer practices and actions described in  
17          subparagraph (A), if any, that could be imple-  
18          mented to improve infant formula supply and  
19          safety.”.